[The therapeutic potential of endothelial progenitor cells in ischaemic stroke.]

[The therapeutic potential of endothelial progenitor cells in ischaemic stroke.] Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

[The therapeutic potential of endothelial progenitor cells in ischaemic stroke.] Abstract Text:

M Navarro-Sobrino,A Rosell,M Hernandez-Guillamon,E Cuadrado,J Montaner,M Navarro,A Rosell,M ,E Cuadrado,J Montaner,

AIM. To review the present knowledge about endothelial progenitor cells (EPCs), their relationship with stroke and their possible therapeutic potential. DEVELOPMENT. Activation of angiogenesis and vasculogenesis after cerebral ischemia is an attempt to recover damaged cerebral tissue. The role of EPCs in angiogenesis/vasculogenesis after brain ischemia remains unknown. Many studies have been published about the isolation, phenotyping and function of EPCs. However, there is not a unique definition for these cells; their origin and function are still an issue of controversy between different research groups. In this review, we summarize the currently used techniques and the most relevant publications about EPCs in experimental models of cerebral ischemia and their role in stroke. CONCLUSIONS. The identification of EPCs in peripheral blood as hematopoietic cells with the ability to differentiate into endothelial cells, broke the paradigm that vasculogenesis was only an embryogenic process. However, better knowledge about the origin and function of EPCs in cerebral ischemia is required. Stimulation of these cells opens a wide new field of cell-based angiogenic therapy that could improve the current stroke treatment.

[The therapeutic potential of endothelial progenitor cells in ischaemic stroke.] Publishing Authors By Initials

M Navarro-Sobrino,A Rosell,M Hernandez-Guillamon,E Cuadrado,J Montaner,M Navarro,A Rosell,M ,E Cuadrado,J Montaner,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

[The therapeutic potential of endothelial progenitor cells in ischaemic stroke.] Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Revista de neurologia

VOLUME: 45

Page Numbers: 556-62

Journal Abbreviation:

ISSN: 0210-0010

DAY: 5

MONTH: 11

YEAR: 2007

[The therapeutic potential of endothelial progenitor cells in ischaemic stroke.] Information

Number of References:

LANGUAGE: spa

NlmUniqueID: 7706841

[The therapeutic potential of endothelial progenitor cells in ischaemic stroke.] Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: [The therapeutic potential of endothelial progenitor cells in ischaemic stroke.] Information

Substance Name:

Registry Number:

Grant and Affiliation Information for [The therapeutic potential of endothelial progenitor cells in ischaemic stroke.]

AFFILIATION: Hospital General Universitari Vall d'Hebron, Barcelona, Espana.

Country: Spain

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Rev Neurol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

The therapeutic potential of endothelial progenitor cells in ischaemic stroke Related Publications

• A large prospective study assessing injection site reactions, quality of life and preference in patients using the Biojector vs standard needles for enfuvirtide administration.
• A review of barriers and facilitators of HIV treatment among injection drug users.
• Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: the role of methadone maintenance therapy.
• Baseline viral load and immune activation determine the extent of reconstitution of innate immune effectors in HIV-1-infected subjects undergoing antiretroviral treatment.
• Cholesterol measured before stroke thrombolysis is not associated with tissue plasminogen activator related hemorrhagic transformation.
• Directly observed therapy programmes for anti-retroviral treatment amongst injection drug users in Vancouver: access, adherence and outcomes.
• Early and delayed benefits of HIV-1 suppression: timeline of recovery of innate immunity effector cells.
• Ethical and scientific issues surrounding solid organ transplantation in HIV-positive patients: Absence of evidence is not evidence of absence.
• Fas system activation in perihematomal areas after spontaneous intracerebral hemorrhage.
• Genetics of stroke: a review of recent advances.
• Highly active antiretroviral therapy and survival in HIV-infected injection drug users.
• Impact of HIV testing on uptake of HIV therapy among antiretroviral naive HIV-infected injection drug users.
• Increased soluble vascular cell adhesion molecule-1 plasma levels and soluble intercellular adhesion molecule-1 during antiretroviral therapy interruption and retention of elevated soluble vascular cellular adhesion molecule-1 levels following resumption
• Is nevirapine-based therapy discontinuation in hepatitis C co-infected patients a more important mortality determinant than hypersensitivity: authors' reply.
• MMP-9-positive neutrophil infiltration is associated to blood-brain barrier breakdown and basal lamina type IV collagen degradation during hemorrhagic transformation after human ischemic stroke.
• Microarray data on gene modulation by HIV-1 in immune cells: 2000-2006.
• Moderate and severe traumatic brain injury induce early overexpression of systemic and brain gelatinases.
• NK cell lysis of HIV-1-infected autologous CD4 primary T cells: requirement for IFN-mediated NK activation by plasmacytoid dendritic cells.
• Outcomes of multidrug-resistant patients switched from enfuvirtide to raltegravir within a virologically suppressive regimen.
• Progression of symptomatic intracranial large artery atherosclerosis is associated with a proinflammatory state and impaired fibrinolysis.
• Rates of HIV/AIDS care and antiretroviral therapy response among active injection drug users.
• Should active recruitment of health workers from sub-Saharan Africa be viewed as a crime?
• Tenofovir-based rescue therapy for advanced liver disease in 6 patients coinfected with HIV and hepatitis B virus and receiving lamivudine.
• The Canadian government's treatment of scientific process and evidence: inside the evaluation of North America's first supervised injecting facility.
• The use of highly active retroviral therapy to reduce HIV incidence at the population level.
• Tissue plasminogen activator (t-PA) promotes neutrophil degranulation and MMP-9 release.
• Transmission of drug-resistant HIV-1 from an infected individual to a caregiver.
• [Biological markers in spontaneous intracerebral hemorrhage]
• [Commentary] ANTIRETROVIRAL THERAPY: A KEY PART OF THE PUBLIC HEALTH RESPONSE TO INJECTION DRUG USE.
• [The therapeutic potential of endothelial progenitor cells in ischaemic stroke.]